|1.||Ke, Yuan-nan: 2 articles (10/2013 - 09/2013)|
|2.||Yang, Han-yue: 2 articles (10/2013 - 09/2013)|
|3.||Jin, Hao: 2 articles (10/2013 - 09/2013)|
|4.||Wang, Yun: 2 articles (10/2013 - 09/2013)|
|5.||Jiao, Yuan: 2 articles (10/2013 - 09/2013)|
|6.||Zheng, Jia-tong: 2 articles (10/2013 - 09/2013)|
|7.||Chen, Li: 2 articles (10/2013 - 09/2013)|
|8.||Liu, Mei-xia: 1 article (10/2013)|
|9.||Wang, Bang-yu: 1 article (10/2013)|
|10.||Wang, Lin: 1 article (10/2013)|
06/01/2000 - "Glomerular sclerosis, however, was less pronounced in the aranidipine-treated group than in the M-1 group. "
06/01/2000 - "The decreases in proteinuria were observed in the aranidipine-treated group at weeks 6, 8, and 10, whereas in the M-1 group, significant reduction was attained only at week 6. Histopathologic examination revealed that both treatments improved glomerular and arteriolar sclerosis. "
|3.||Hypertension (High Blood Pressure)
10/22/2013 - "[Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension]."
09/01/2013 - "Administration of aranidipine enteric-coated capsules can control 24 h blood pressure effectively and reduce BPV significantly in patients with mild to moderate essential hypertension with good safety profile."
09/01/2013 - "To evaluate the effect of aranidipine enteric-coated capsules on 24 h blood pressure and blood pressure variability (BPV) in patients with mild to moderate essential hypertension. "
09/01/2013 - "[The effects of aranidipine on ambulatory blood pressures in patients with mild to moderate essential hypertension]."
07/01/1993 - "Because of this cardiovascular profile, MPC-1304 should be useful in treatment of hypertension as well as angina pectoris."
05/01/1994 - "Thus, MPC-1304 had antihypertensive effects in stroke-prone spontaneously hypertensive rats."
05/01/1994 - "The effects of MPC-1304, a newly developed 1,4-dihydropyridine derivative, on blood pressure and hypertensive complications in stroke-prone spontaneously hypertensive rats fed a high-salt diet (0.8% NaCl), were investigated. "
05/01/1994 - "Effects of MPC-1304, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats."
05/01/1994 - "Treatment with MPC-1304 inhibited the incidence of cerebral stroke, cardiac fibrosis, proliferative and fibrinoid arteriolitis and malignant nephrosclerosis. "
|7.||Calcium Channels (Calcium Channel)
|9.||Enteric-Coated Tablets (Tablets, Enteric Coated)